Ninlaro (ixazomib) is an oral targeted therapy anticancer drug that is used in combination with lenalidomide (Revlimid) and dexamethasone to treat multiple myeloma (MM).

Clinical trials have been completed using combination treatment of Ninlaro, lenalidomide (Revlimid) and dexamethasone against the combination treatment of placebo, lenalidomide (Revlimid) and dexamethasone.

How effective is Ninlaro?

Clinical trials have shown that Ninlaro is more effective than the medicines it was trialed against, in treating multiple myeloma.

• Ninlaro was faster at getting a response than the other treatment group in the clinical trial.

• Ninlaro delayed the progression of the illness longer than the other treatment group.

• Patients who trialled Ninlaro had a higher level of positive responses compared to other treatment group

• Ninlaro worked very well in high risk cytogenetic patients, patients with stage III illness and patients older than 75 years old

How long does it take to get a first response from treatment?

Time for response was faster in the Ninlaro group compared to the placebo group.

• The Ninlaro group took 1.1 month to get a response and the placebo group response took 1.9 months.